Vanda Pharmaceuticals Inc (VNDA)
4.98
-0.25
(-4.78%)
USD |
NASDAQ |
May 28, 16:00
4.98
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Gross Profit (TTM): 164.14M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 164.14M |
December 31, 2023 | 177.84M |
September 30, 2023 | 194.28M |
June 30, 2023 | 217.52M |
March 31, 2023 | 233.30M |
December 31, 2022 | 230.10M |
September 30, 2022 | 233.64M |
June 30, 2022 | 237.94M |
March 31, 2022 | 240.94M |
December 31, 2021 | 243.05M |
September 30, 2021 | 242.51M |
June 30, 2021 | 233.62M |
March 31, 2021 | 228.65M |
December 31, 2020 | 224.80M |
September 30, 2020 | 218.27M |
June 30, 2020 | 216.56M |
March 31, 2020 | 212.89M |
December 31, 2019 | 202.70M |
September 30, 2019 | 195.37M |
June 30, 2019 | 186.73M |
March 31, 2019 | 176.18M |
December 31, 2018 | 172.61M |
September 30, 2018 | 164.72M |
June 30, 2018 | 157.46M |
March 31, 2018 | 152.86M |
Date | Value |
---|---|
December 31, 2017 | 147.24M |
September 30, 2017 | 140.72M |
June 30, 2017 | 135.40M |
March 31, 2017 | 127.41M |
December 31, 2016 | 121.30M |
September 30, 2016 | 114.01M |
June 30, 2016 | 104.35M |
March 31, 2016 | 96.63M |
December 31, 2015 | 86.46M |
September 30, 2015 | 75.47M |
June 30, 2015 | 67.72M |
March 31, 2015 | 56.56M |
December 31, 2014 | 48.57M |
September 30, 2014 | 42.67M |
June 30, 2014 | 37.30M |
March 31, 2014 | 34.95M |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 31.27M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
164.14M
Minimum
Mar 2024
243.05M
Maximum
Dec 2021
216.74M
Average
221.54M
Median
Gross Profit (TTM) Benchmarks
ADMA Biologics Inc | 111.54M |
INVO Bioscience Inc | 1.676M |
Johnson & Johnson | 61.53B |
Nektar Therapeutics | 54.92M |
Ligand Pharmaceuticals Inc | 108.64M |